Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual’s quality of life and daily functioning. In recent years, enhanced understanding of the pathogenesis of psoriasis, especially the role of T helper 17 cells, has resulted in the development of new classes of biologic drugs targeting modulators along its disease pathway. Among these, inhibitors of interleukin-23 (e.g., ustekinumab, guselkumab, tildrakizumab, and risankizumab) have emerged as safe and effective options for the treatment of moderate-to-severe plaque psoriasis; ustekinumab and guselkumab have additionally been approved to treat psoriatic arthritis. Selective interleukin-23 inhibitors require less frequent dosing than interleukin-17 inhibitors and may possess a more favorable risk profile without an increased risk of candidiasis or inflammatory bowel disease. Overall, these highly effective medications are contributing to a rising standard for psoriasis outcomes through resolution of skin lesions and joint manifestations and improvement of patient quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
IL-17–Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans
Conti, H. R., & Gaffen, S. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500909 · Cited by 301
Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution
Cheng, J. B., Sedgewick, A. J., Finnegan, A. I., Harirchian, P., Lee, J., Kwon, S., Fassett, M. S., Golovato, J., Gray, M., Ghadially, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.006 · Cited by 284
Cited by
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Immune-mediated inflammatory diseases: common and different pathogenic and clinical features
Monteleone, G., Moscardelli, A., Colella, A., Marafini, I., & Salvatori, S. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103410 · Cited by 105
A closer look at the mycobiome in Alzheimer’s disease: Fungal species, pathogenesis and transmission
Phuna, Z. X., & Madhavan, P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15599 · Cited by 41
“IL-23 inhibitors have resulted in promising therapies against plaque psoriasis (Chan et al., 2018; Yang et al., 2021).”
BackgroundAndrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“However, this phenomenon remains a subject of ongoing clinical research [135,156–159].”
Metadata
- Authors
- Yang, K., Oak, A. S. W., & Elewski, B. E.
- Venue
- American Journal of Clinical Dermatology
- Published
- 2020-12-10
- Volume
- 22
- Issue
- 2
- Pages
- 173-192
- ISSN
- 1175-0561 (ISSN-L)
- 1179-1888
- OpenAlex
- W3113161927
- Cited by
- 185
- References
- 4
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. https://app.cochat.ai/papers/10.1007/s40257-020-00578-0
- The paper
- Yang, K., Oak, A. S. W., & Elewski, B. E. (2021). Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-020-00578-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.